HedgeCo.Net — Albert Invent raised a $55 million Series B led by TCV at a reported valuation of about $340 million to expand its chemistry-native AI platform, according to the company’s announcement and coverage by Yahoo Finance and Forbes’ The Prompt. New investors in the round include Delta-v Capital, Socium, HighSage, Coral and Legion, while existing backers also returned.
Albert builds AI tools designed around chemical discovery and development workflows rather than generic large-language models bolted onto lab software. The company has highlighted its Valence technology as part of that chemistry-native stack, aiming to shorten iteration cycles for materials and specialty chemical teams that still rely heavily on experimental trial and error.
A TCV-led Series B at a mid-hundreds-of-millions valuation places Albert among the better-capitalized vertical AI companies selling into industrial R&D. Participation from both new specialist and generalist investors, alongside returning shareholders, suggests the round was positioned as a growth step rather than a distressed bridge.
The capital is expected to fund product development and go-to-market expansion as more chemical and materials companies look for AI systems that understand molecular constraints, not only document search or lab scheduling. That distinction matters for venture underwriting: chemistry-native models can be harder to build, but switching costs may be higher once they are embedded in discovery pipelines.
For venture and crossover allocators, Albert’s raise is another data point that vertical AI with domain-specific architecture continues to clear at premium prices when the end market is large and digitally underpenetrated. The reported $340 million valuation will be judged against how quickly the company converts R&D budgets into recurring software revenue.